Tan Xiang, Kang Le, Chen Hao, Liu Xingyan, Du Chi
Department of Hematology and Oncology, The People's Hospital of An'yue, Ziyang, Sichuan 642350, P.R. China.
Department of Oncology and Hematology, The People's Hospital of Dujiangyan, Chengdu, Sichuan 611132, P.R. China.
Oncol Lett. 2025 May 19;30(1):352. doi: 10.3892/ol.2025.15098. eCollection 2025 Jul.
This report presents the case of a 53-year-old man who was diagnosed with hepatocellular carcinoma and developed lung metastasis after undergoing surgery and interventional treatment. The lung metastasis progressed multiple times while the patient was undergoing successive treatments with Lenvatinib, Apatinib combined with Camrelizumab and Regorafenib. Eventually, a positive response was achieved with Tislelizumab combined with Xelox. The patient has been receiving Tislelizumab combined with Xelox for 23 months and has maintained a complete response to treatment. This case indicates that combining immune rechallenge with chemotherapy is beneficial for metastatic hepatocellular carcinoma.
本报告介绍了一名53岁男性的病例,该患者被诊断为肝细胞癌,在接受手术和介入治疗后发生了肺转移。在患者接受乐伐替尼、阿帕替尼联合卡瑞利珠单抗和瑞戈非尼的连续治疗期间,肺转移多次进展。最终,替雷利珠单抗联合XELOX方案取得了阳性反应。该患者接受替雷利珠单抗联合XELOX方案治疗已达23个月,且一直维持对治疗的完全反应。该病例表明,免疫再激发联合化疗对转移性肝细胞癌有益。